FibroGen, Inc. (FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of chemotherapy-induced anemia (CIA) in cancer patients...
Scientists at the University of Strathclyde researching a system to measure and monitor blood chemistry levels in premature and sick babies through their skin Scientists at the University of Strathclyde are researching a system to measure and monitor blood chemistry...
Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra) today announced that it will host an ePoster presentation and discussion of the company’s ALLEVIATE Phase 3 clinical trial of reproxalap in patients with allergic conjunctivitis at the American Academy of Ophthalmology 2019...
-Patients treated at the high dose show impressive survival benefit–IL4R population surviving twice as long as current approved treatments- TORONTO and HOUSTON, Sept 25, 2019 /PRNewswire/ – Medicenna Therapeutics Corp. (“Medicenna” or...
Incyte (Nasdaq:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult patients (age ≥12 years) with vitiligo. “The...
Email
Text